// App-Quantinova.ai

: Empagliflozin reduces heart failure irrespective of control of blood pressure, low density lipoprotein cholesterol and HbA1c

Researchers

Presenter

  • D. Fitchett

Principal Investigators

  • J. McKnight

  • J. Lee

  • J. George

  • M. Mattheus

  • H.J. Woerle

  • S.E. Inzucchi

Medical Centers

  • St. Michael's Hospital, Division of Cardiology, University of Toronto, Toronto, Canada

  • Western General Hospital, Edinburgh, United Kingdom

  • Boehringer Ingelheim Pharma GmbH, Ingelheim, Germany

  • Section of Endocrinology, Yale University School of Medicine, New Haven, United States of America

Locations

  • Canada

  • United Kingdom

  • Germany

Companies

  • Boehringer Ingelheim

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

Disease

  • N/A

Biomarkers

  • Hemoglobin A1c

Drug/Treatment

  • BI-10773

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved